TARPLIN, DOWNS & YOUNG, LLC

Lobbying for HANSA BIOPHARMA · Biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $60,000.00 income · posted Jul 20, 2026

Lobbying activity 2

Budget/Appropriations

Federal budget issues

Health Issues

Kidney issues, access to innovation, rare disease issues, organ rejection

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.